149,994 members

Skip to content. | Skip to navigation

News

Greater options for patients with type 2 diabetes

 

Start sharing

If you've got news you'd like to share, let us know and we'll consider it for our news section.
 

Greater options for patients with type 2 diabetes

NICE has approved the use of exenatide in triple therapy regimens for patients with type 2 diabetes, in latest guidance.

Patients should be offered the drug if they are struggling to control their blood glucose levels or if they remain inadequate, defined as an HbA1c of 7.5 per cent or above, or other higher level as agreed with the individual.

Exenatide improves glycaemic control in a number of ways, such as by enhancing glucose-dependent insulin secretion to help lower the rise in blood sugar from eating. More …..